Loading…
Immunovant, Inc. is projected to rise to $55.58 by 2027, a +40% move from its current price of $39.71. IMVT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $38.80 | $39.72 | $40.66 | +0.02% |
| Jul 13 | $38.44 | $39.73 | $41.07 | +0.05% |
| Jul 14 | $38.16 | $39.74 | $41.38 | +0.07% |
| Jul 15 | $37.93 | $39.75 | $41.65 | +0.09% |
| Jul 16 | $37.73 | $39.76 | $41.89 | +0.12% |
| Jul 17 | $37.55 | $39.77 | $42.11 | +0.14% |
| Jul 18 | $37.39 | $39.78 | $42.32 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $37.39 | $39.78 | $42.32 | +0.17% |
| Week 2 | $36.50 | $39.84 | $43.49 | +0.33% |
| Week 3 | $35.85 | $39.91 | $44.42 | +0.50% |
| Week 4 | $35.32 | $39.97 | $45.24 | +0.66% |
| Week 5 | $34.86 | $40.04 | $45.98 | +0.83% |
| Week 6 | $34.46 | $40.11 | $46.67 | +1.00% |
| Week 7 | $34.10 | $40.17 | $47.32 | +1.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunovant, Inc. is a clinical-stage immunology company that develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc. trades under the symbol IMVT and is in the Healthcare sector. The current price is $41.09 per share. The stock has a market capitalization of $8.44B and is ranked 1031 by market capitalization and liquidity measures.
At the near term, the forecast path shows upside potential with an average price of $41.09 in 2026 and a bullish trajectory continuing through the forecast horizon, culminating in an average price of $433.21 by 2050 and a maximum forecast of $753.71. The expected ROI grows from 0% in 2026 to 954.3% by 2050, supported by a bullish sentiment across the longer term.
A major floor 42.1% below — a decisive break under it would weaken the trend.
The nearest floor, 22.4% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 19.6% above — clearing it would confirm fresh momentum.
Key IMVT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMVT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $39.96 | Sell | $39.90 | Sell |
| MA 10 | $39.26 | Buy | $39.17 | Buy |
| MA 20 | $37.42 | Buy | $37.57 | Buy |
| MA 50 | $33.13 | Buy | $34.12 | Buy |
| MA 100 | $29.62 | Buy | $30.95 | Buy |
| MA 200 | $26.33 | Buy | $27.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.85 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 72.98 | Neutral |
| Williams %R (14) | -39.77 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 5.56 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 60.23 | Neutral |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 4.58 | Buy |
| Ultimate (7,14,28) | 65.01 | Neutral |
| Momentum (10) | 1.47 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 40.88 | Sell |
| ADX (14) | 33.20 | Buy |
| ATR (14) | 0.76 | Info |
The 30-day technical picture is bullish overall. RSI14 is 80, signaling strong momentum, while price sits near a resistance level of $41.09 and above a support level of $30.80. The SMA50 is $32.88 and the SMA200 is $26.21, indicating longer-term upside relative to short-term momentum.
The 30-day range runs from $35.31 to $47.82, illustrating an active trading band within which near-term moves are likely to occur. The outlook is consistent with a bullish posture in the near term, though elevated volatility can keep swings pronounced.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.98 | $39.71 | $53.58 | 0% | Neutral | |
| $44.83 | $55.58 | $72.52 | +40% | Bullish | |
| $49.25 | $62.50 | $84.23 | +57% | Bullish | |
| $51.92 | $67.19 | $92.88 | +69% | Bullish | |
| $59.31 | $78.08 | $110.26 | +97% | Bullish | |
| $59.88 | $80.06 | $115.20 | +102% | Bullish | |
| $63.58 | $86.24 | $126.20 | +117% | Bullish | |
| $78.66 | $108.14 | $160.70 | +172% | Bullish | |
| $88.71 | $123.53 | $186.16 | +211% | Bullish | |
| $95.81 | $135.04 | $206.21 | +240% | Bullish | |
| $129.92 | $193.46 | $312.17 | +387% | Bullish | |
| $240.90 | $393.65 | $688.82 | +891% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $22.98 | $39.71 | $47.36 | +0.00% |
| August 2026 | $33.59 | $39.50 | $47.60 | -0.52% |
| September 2026 | $34.30 | $40.57 | $49.35 | +2.71% |
| October 2026 | $35.72 | $42.48 | $52.09 | +4.69% |
| November 2026 | $35.93 | $42.91 | $52.98 | +1.03% |
| December 2026 | $35.98 | $43.14 | $53.58 | +0.52% |
Click any year to see its month-by-month IMVT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMVT is projected to trade between $22.98 and $53.58, averaging $39.71 — a potential gain of 0% from today's $39.71. A consolidation phase looks the most probable path here.
Immunovant, Inc.'s 2027 outlook centres on $55.58, within a $44.83 to $72.52 range. That is up +40% on the projected 2026 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2028, IMVT could reach as high as $84.23, with a base case around $62.50 and support toward $49.25 — roughly +57% from $39.71. Buyers look set to stay in control over this stretch.
Expect IMVT to range from $51.92 to $92.88 through 2029. The $67.19 average target implies a +69% move from current prices. That is up +8% on the projected 2028 average. Momentum favours further upside here.
The IMVT price prediction for 2030 points to an average of $78.08 (low $59.31, high $110.26) — a potential gain of +97% on today's $39.71. Buyers look set to stay in control over this stretch.
In 2031, IMVT is projected to trade between $59.88 and $115.20, averaging $80.06 — a potential gain of +102% from today's $39.71. That is up +3% on the projected 2030 average. Momentum favours further upside here.
Immunovant, Inc.'s 2032 outlook centres on $86.24, within a $63.58 to $126.20 range. That is up +8% on the projected 2031 average. That marks a +117% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMVT could reach as high as $160.70, with a base case around $108.14 and support toward $78.66 — roughly +172% from $39.71. Momentum favours further upside here.
Expect IMVT to range from $88.71 to $186.16 through 2034. The $123.53 average target implies a +211% move from current prices. That is up +14% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMVT price prediction for 2035 points to an average of $135.04 (low $95.81, high $206.21) — a potential gain of +240% on today's $39.71. Momentum favours further upside here.
In 2040, IMVT is projected to trade between $129.92 and $312.17, averaging $193.46 — a potential gain of +387% from today's $39.71. That is up +43% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Immunovant, Inc.'s 2050 outlook centres on $393.65, within a $240.90 to $688.82 range. That is up +103% on the projected 2040 average. That marks a +891% change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMVT today (≈ 25.182574 IMVT) could be worth
$9,913.2
+$8,913.2 (+891%) by 2050 · US Dollar
Based on the average projected IMVT price of $393.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMVTwould be worth at today's price.
$1,000 invested in IMVT on Jul 10, 2025 (≈ 57.142857 IMVT) would be worth
$2,269.14
+$1,269.14 (+126.9%) today · 2.27× · US Dollar
Based on a IMVT entry price of $17.5 vs. today's $39.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.79 | $1,023.72 | +2.4% |
| 1 month ago | $31.18 | $1,273.57 | +27.4% |
| 3 months ago | $24.5 | $1,620.82 | +62.1% |
| 6 months ago | $25.81 | $1,538.55 | +53.9% |
| 1 year ago | $17.5 | $2,269.14 | +126.9% |
| All time (5.0y) ago | $10.62 | $3,739.17 | +273.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMVT forecast.
Our base-case forecast reaches $79.00 around 2031.
Implied market cap at $79.00: $16.22B
The multi-year forecast points to a pronounced long-term uptrend. In 2026 the average price is $41.09 with an ROI of 0% (neutral). By 2027 the average is $57.96 with a 41% ROI, and by 2028 the average is $65.40 with a 59.2% ROI. The path continues higher through 2029 at $70.78 (72.3% ROI) and 2030 at $82.63 (101.1% ROI).
From 2031 onward, the averages reach $85.14 (107.2% ROI) and $92.44 (125% ROI) in 2032 and 2033, respectively, rising to $116.48 in 2033 with a 183.5% ROI, then to $132.87 in 2034 (223.4% ROI) and $145.46 in 2035 (254% ROI).
The forecast extends to 2040 with an average of $211.69 and a 415.2% ROI, and by 2050 the average is $433.21 with a max of $753.71 and a 954.3% ROI. The sentiment remains bullish across the long horizon, recognizing substantial upside but acknowledging the inherent uncertainty in future price paths.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $82.63, with a low of $62.92 and a high of $116.34. The expected ROI is 101.1%.
Forecasts show bullish sentiment from 2027 onward, with averages rising to $57.96 in 2027, $433.21 by 2050, and an ROI up to 954.3%.
Yes, the 2030 max forecast is $116.34.
Min $22.98, Avg $41.09, Max $55.68.
Current price $41.09; Market cap $8.44B.
Immunovant, Inc. Community Discussion
0Share your Immunovant, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.